In a cohort of 102 patients with EGFR mutant lung cancer, the real-time PCR by cobas® EGFR Mutation Test v2 has shown a concordance for EGFR p. L858R and exon 19 deletion to matched tissue samples of 87.4%, a sensitivity for detection of the EGFR mutations of 70.6%, and a specificity of 91.7%. The gene discussed is EGFR; the disease is lung carcinoma.